Gland Pharma Limited reported a sharp decline in its consolidated net profit for the fourth quarter ended March 31, 2025 (Q4 FY25). The company posted a net profit of ₹186.5 crore, down 3.1% from ₹192.4 crore in the year-ago period and 8.9% lower than ₹204.7 crore reported in Q3 FY25.
Revenue from operations also declined by 7.3% year-on-year to ₹1,424.9 crore compared to ₹1,537.4 crore in Q4 FY24. Total income for the quarter stood at ₹1,468.9 crore, down from ₹1,579.6 crore a year earlier.
Expenses were brought under control, with total costs at ₹1,180.6 crore versus ₹1,281.3 crore in the same quarter last year. Profit before tax came in at ₹288.3 crore, marginally down from ₹298.2 crore in Q4 FY24.
For the full financial year FY25, net profit declined 9.6% to ₹698.5 crore from ₹772.4 crore in FY24. Revenue from operations also saw a slight drop to ₹5,616.5 crore from ₹5,664.7 crore in the previous fiscal year.
The company’s bottom line pressure reflects a mix of operational headwinds and weaker topline performance amid a competitive market landscape.
